RECOMBINANT HUMAN (EGF) MARKET ANALYSIS

Recombinant Human (EGF) Market, by Product Type (Heparin Binding-EGF, Transforming Growth Factor-α, Epigen, Neuregulins, Amphiregulin, Betacellulin, and Others), by Purity (98% SDS-PAGE, 95%-98% SDS-PAGE, and <95% SDS-PAGE), by Carrier Type (Carrier Protein and Carrier Free), by Formulation (Lyophilized Powder, Liquid, and Others), by Application (Wound Healing, Gastrointestinal Ulceration, Brain Tumor Therapy, and Others)and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Jul 2021
Code : CMI4515
Pages :157
Formats :
Excel and PDF
Industry : Medical Devices

Regional Analysis

Global Recombinant Human EGF Market – Regional Analysis

On the basis of region, the global recombinant human EGF market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global recombinant human EGF market over the forecast period, owing to rising incidence of diabetes. For instance, according to National Diabetes Statistics Report- 2020 by Centers of Disease Control and Prevention, around 34.2 million people in the U.S. have diabetes while 34.5% of the U.S population are prediabetic. This is expected to boost the market growth of recombinant human EGF market as the rhEGFs are widely used for the treatment of diabetic foot ulcers.

Figure 2: Global Recombinant Human EGF Market Value (US$ 3,987.7 Mn), by Region, 2021

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa